(1838 - 1904)
Zoólogo, botánico y médico. Desarrolló una amplia labor en la Real Sociedad Económica de Amigos del País de La Habana. Autor de un depurado estilo literario, dio a conocer numerosas contribuciones científicas.
Biomedical Sciences
1996 | Identification of new biological functions of the Transference Factor
Main author: Miriam Ojeda Ojeda
Summary: The Transference Factor has been widely used in our country (TF) in the therapy of multiple entities that study immunodeficiency starting from its production in the CIB, using activated human leukocytes. The characterization of this preparation and the identification of its biological functions has been a challenge for the development of its clinical application and commercializations of the product, taking into account its complex character and origin. This work defines two new biological activities of the preparation: the replication inhibition of VIII and the production inhibition of the Tumoral Necrosis Factor (TNF) for activated human leukocytes. It has also been possible to obtain fractions of the TF preparation enriched in both effects. The inhibition of HIV production is observed when incubating line cells with TF or its active fraction, during seven days previous to the viral challenge. There are reached inhibition levels of virus production higher than 80%, for viral doses of 0,05-0,1 m.o.i. The isolated active fraction achieves inhibitory levels higher than 80%, even with viral doses 10 times higher. On the other hand, the treatment of isolated human monocytes or of total blood with TF, simultaneous or even 1 h after the addition of the inductive stimulus (LPS), is able to block the production of TNF. Both effects point out TF action mechanisms in its therapeutic use in asymptomatic HIV-positive individuals, where a significant reduction has been achieved in the progression to AIDS. On the other hand, the inhibitory capacity of TNF production sustains the therapeutic application of the product in diseases that have inflammatory manifestations, and where its preliminary use was only guided to the immune response's modulation, like in the case of bronchial asthma and septic syndrome. The demonstration of combination of immunomodulator and anti-inflammatory effects on the TF creates important evaluation areas of its therapeutic application, those previously described and others where the TNF plays a pathological role as in rheumatoid arthritis and some parasitic infections. This work contributes to the identification of pharmacological action mechanisms, to the demonstration of new indications, and to the characterization of the product marketed as Hebertrans.